MEETINGS - Workshop on Biotechnology: Global Perspectives (US) March 2000:
This article was originally published in Clinica
Executive Summary
The Drug Information Association will hold its 8th Annual DIA Biotechnology Workshop - Biotechnology: Global Perspectives in Dana Point, California, US on March 6-7. Topics for discussion include: regulatory policy - interpretation and impact; US and global policy; clinical trials methodology and strategies; current issues for blood and blood products; genetically engineered products: developments and challenges. For more information contact DIA in the US. Tel: +1 215 628 2288. Fax: +1 215 641 1229. Email: [email protected]
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.